Keybanc Maintains Overweight on Bio-Techne, Lowers Price Target to $80
Portfolio Pulse from Benzinga Newsdesk
Keybanc analyst Paul Knight has maintained an Overweight rating on Bio-Techne (NASDAQ:TECH) but lowered the price target from $115 to $80.
November 01, 2023 | 9:52 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Bio-Techne's price target has been lowered from $115 to $80 by Keybanc, though the Overweight rating is maintained.
The lowering of the price target by Keybanc indicates a potential decrease in the stock's value. However, the maintained Overweight rating suggests that the stock is still expected to outperform. This mixed signal could lead to short-term uncertainty and potential downward pressure on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100